Why the study?
Whether ticagrelor or prasugrel is beneficial compared with clopidogrel in patients undergoing PCI for CCS with high thrombotic and low bleeding risk warrants further study.
Does ticagrelor or prasugrel improve 1-year efficacy and safety compared to clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes?
Does ticagrelor or prasugrel improve 1-year efficacy and safety compared to clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes?
Ticagrelor and prasugrel demonstrate similar 1-year efficacy and safety compared to clopidogrel in CCS patients undergoing PCI, though their specific benefit in high thrombotic/low bleeding risk subgroups requires further study.
Answers are grounded in this paper and cite their sources.
Comparable efficacy supports clopidogrel as a reasonable option in CCS-PCI; leaves open targeted use in high-risk subgroups.
Ticagrelor and prasugrel are increasingly used in patients with CCS undergoing PCI with similar 1-year efficacy and safety when compared to clopidogrel. Whether use of these agents can be beneficial in patients undergoing PCI for CCS with a high thrombotic and low bleeding risk warrants further study.
No takes yet. Share an insight, caveat, or question.
Koshy et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: